Thomas Tamlyn, MD
Interventional Cardiology · Appleton, WINPI 1831176338
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,172 and has fallen 68.0% since, to $375 in 2025. That places this record below the midpoint for interventional cardiology clinicians in WI, where the typical reported total is $3,713.
Across 94 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$448
- Novartis$437
- Johnson & Johnson$353
- Medtronic$236
- Amgen$149
- Penumbra, Inc.$148
- plus $1K from 20 others
Across 70 payments — averaging $1544.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$108K
What the payments were for
- Food & beverage$2,67396%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $448 |
| Novartis | 19 | $437 |
| Johnson & Johnson | 16 | $353 |
| Medtronic(2 entities) | 6 | $236 |
| Amgen | 8 | $149 |
| Penumbra, Inc. | 1 | $148 |
| Boston Scientific | 3 | $146 |
| Surmodics, Inc. | 8 | $128 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| Inari Medical, Inc. | 4 | $97 |
| Abiomed | 3 | $81 |
| Cleerly, Inc. | 1 | $75 |
| EKOS Corporation | 1 | $66 |
| AstraZeneca | 4 | $65 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| Heartflow, Inc. | 1 | $25 |
| Pfizer | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Biocompatibles, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Asahi Intecc USA, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Merck | 1 | $13 |
| Angiodynamics, Inc. | 1 | $12 |
| Terumo Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JETI$321
- SYMPLICITY G3$170
- Indigo System$148
- AVVIGO Guidance System$116
How this compares
$2,772 in reported general payments places this provider in the 40th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 467 | $482,551 |
| EntrestoSacubitril/Valsartan | 203 | $176,379 |
| XareltoRivaroxaban | 159 | $151,708 |
| JardianceEmpagliflozin | 98 | $83,287 |
| BrilintaTicagrelor | 63 | $43,826 |
| FarxigaDapagliflozin Propanediol | 49 | $43,025 |
| Repatha SureclickEvolocumab | 21 | $23,950 |
| Metoprolol Succinate | 552 | $9,614 |
| ClopidogrelClopidogrel Bisulfate | 330 | $4,334 |
| Rosuvastatin Calcium | 199 | $3,292 |
| Atorvastatin Calcium | 200 | $2,694 |
| Losartan Potassium | 139 | $2,124 |
| Bumetanide | 46 | $2,114 |
| Nebivolol Hcl | 50 | $1,928 |
| Potassium Chloride | 70 | $1,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $482,551467 claims |
| NovartisEntresto | $437 | $176,379203 claims |
| Johnson & JohnsonXarelto | $353 | $151,708159 claims |
| AstraZenecaBrilinta, Farxiga | $65 | $86,850112 claims |
| Boehringer IngelheimJardiance | $14 | $83,28798 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Appleton
- Cherian VargheseAppleton$10K
- Brian GuttormsenAppleton$6K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.